Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tracking antibiotic levels in the blood improve sepsis care?

NCT ID NCT05413343

Knowledge-focused Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Sep 11, 2026 · Updated 3 times

Summary

This study is tracking how the antibiotic ceftazidime-avibactam behaves in the blood of critically ill patients with severe sepsis. Researchers are collecting blood samples at several time points to measure drug levels and build a model that could help doctors choose the right dose. The goal is to develop better dosing guidelines for patients with different kidney function, including those on dialysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ceftazidime-avibactam
What this could lead to
If successful, this could lead to more precise dosing of ceftazidime-avibactam for critically ill sepsis patients, potentially improving treatment outcomes.
What could go wrong
This is a small observational study with only 30 participants, so findings may not apply to all patients. It measures drug levels but does not test a new treatment or directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

33 people

The number who actually took part.

Started

Jun 2021

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will comprise critically ill adult patients receiving ceftazidime-avibactam (CAZ-AVI) for carbapenem-resistant organism (CRO) infections at the intensive care unit of the First Affiliated Hospital, Zhejiang University School of Medicine.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Critically ill patients with severe sepsis(CRO infections) and treated with CAZ-AVI(culture-confirmed CRO susceptible to CAZ-AVI); * Age ≥ 18 years; * Expected ICU stay ≥48 hours. * Hemoglobin \>70 g/L during the pharmacokinetic blood-sampling period； * The patient or authorized persons agree and sign the informed consent. Exclusion Criteria: * Expected ICU stay \<48 hours. * Pregnant woman.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carbapenem resistant bacterial infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carbapenem resistant bacterial infection Severe sepsis

Contacts and locations

Locations

  • The First Affiliated Hospital,College of Medicine,Zhejiang University

    Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.